damianrasch.com

Cardio-Oncology: How Cancer Treatment Affects the Heart

Medically Reviewed & Edited

Board-Certified Invasive Cardiologist
Encinitas and La Jolla, CA

Developed with digital research and writing assistance, then medically reviewed and edited by Dr. Rasch to ensure clinical accuracy and adherence to current evidence-based guidelines.

You've just been told you need chemotherapy, and your oncologist mentioned, almost in passing, that one of the drugs can affect the heart. Maybe they used the word cardiotoxicity. Maybe they ordered an echocardiogram before treatment starts. Maybe a friend went through the same chemo years ago and now has heart failure, and you're wondering if you're walking into the same outcome. Or you finished cancer treatment a decade ago, your oncologist signed off, and now your primary care doctor is asking whether you've ever had your heart checked since.

All of those situations land in my clinic on a regular basis. The intersection of cancer care and cardiology has its own subspecialty now, called cardio-oncology, and the field exists because we've gotten so good at curing cancer that the heart has become the long pole in survivorship. This article walks through which cancer treatments can hurt the heart, how we watch for trouble during chemo, what we do if heart numbers slip, and how we follow survivors for years after the cancer is gone.

The throughline I want you to leave with: most patients who go through cardiotoxic cancer treatment do not develop heart failure. The ones who do, we usually catch early, and we treat. The era of "your chemo wrecked your heart and there's nothing we can do" is mostly behind us.

What Cardio-Oncology Actually Means

Cardio-oncology is a clinic and a way of thinking. The clinic part is straightforward. A cardiologist with extra training in cancer-related heart problems sees patients before, during, and after cancer treatment, working alongside the oncology team. The way of thinking is the part that matters more. We hold two goals in our heads at once. First, the cancer treatment has to keep working. Stopping chemo to protect the heart is sometimes the right call, and it's a serious cost, since the cancer doesn't pause while we sort out the heart. Second, the heart has to come through the treatment in good enough shape that it doesn't shorten the life the cancer treatment just saved.

The whole field is a balancing act between those two goals, and that's why it helps to have a cardiologist looking at your case alongside your oncologist. We're not there to overrule the oncology team. We're there to keep the heart from becoming the reason the cancer plan has to change.

Which Cancer Drugs Affect the Heart, and How

Not every cancer treatment puts the heart at risk. The list of drugs that do is well defined, and the patterns of injury are different enough that I want to walk through them by category.

Anthracyclines (Doxorubicin / Adriamycin and Cousins)

Anthracyclines are an old, powerful family of chemotherapy drugs. Doxorubicin, often called by the trade name Adriamycin, is the most familiar. Daunorubicin, epirubicin, and idarubicin are in the same family. They show up in regimens for breast cancer, lymphoma, leukemia, and sarcoma, among others, and they save lives. They also damage heart muscle cells in a dose-dependent way. The more total drug you receive over your lifetime, the higher the risk of weakening of the heart muscle.

The injury can show up during treatment, in the months after, or years later. A patient who finishes chemo with a normal echocardiogram can still develop heart muscle weakening five or ten years downstream. That's part of why cancer survivors who got anthracyclines need long-term heart surveillance whether or not they feel fine.

The risk goes up with higher cumulative dose, with older age, with preexisting high blood pressure or diabetes, with chest radiation given around the same time, and with combinations that include trastuzumab. A patient receiving a low total dose for early-stage breast cancer carries a much smaller risk than a patient receiving the high cumulative doses used for some sarcomas. We can quantify your individual risk reasonably well before you start.

HER2-Targeted Therapy (Trastuzumab / Herceptin)

For HER2-positive breast cancer, trastuzumab (Herceptin) and the related drugs pertuzumab and ado-trastuzumab emtansine have transformed survival. They also can weaken the heart muscle, but in a different pattern than anthracyclines. Trastuzumab-related weakening tends to be reversible. If the pumping function drops, you pause the drug, start heart medications, and most patients recover their heart function within months. The injury usually doesn't accumulate the way anthracycline injury does.

The catch is that trastuzumab is often given right after anthracyclines in breast cancer protocols, and the combination amplifies risk. That's why patients on AC-T or similar regimens get echocardiograms every three months during trastuzumab. We're watching for the dip, ready to pause, and ready to start protective medications fast.

Immune Checkpoint Inhibitors (Pembrolizumab, Nivolumab, Ipilimumab)

Checkpoint inhibitors take the brakes off your immune system so it can attack cancer. They've been game-changing for melanoma, lung cancer, kidney cancer, and a growing list of others. The flipside of revving the immune system up that hard is that it can attack normal tissues, including the heart. The cardiac problem we worry about most is myocarditis, an inflammation of the heart muscle.

Checkpoint inhibitor myocarditis is uncommon, occurring in roughly one percent of patients on these drugs, and most often in the first three months of treatment. When it does happen, it's serious. Symptoms can include chest pain, shortness of breath, palpitations, fatigue, and sometimes the rapid onset of heart failure or dangerous heart rhythms. The mortality rate of severe cases used to be alarmingly high, and earlier recognition and aggressive treatment with high-dose steroids has improved outcomes. Some centers add other immunosuppressive drugs in the worst cases.

If you're on a checkpoint inhibitor and you develop new chest pain, new shortness of breath, palpitations, or unexplained fatigue, contact your oncology team the same day. Don't wait for the next scheduled visit. Most of the time it won't be the heart. We need to rule it out fast on the rare occasions it is.

Kinase Inhibitors (Imatinib, Sunitinib, Ibrutinib, and Others)

Kinase inhibitors are a sprawling group of targeted oral drugs that interrupt specific signaling pathways inside cancer cells. Their cardiac effects vary a lot by drug. Sunitinib, used in kidney cancer and some others, can cause weakening of the heart muscle and high blood pressure. Ibrutinib, used in some leukemias and lymphomas, can trigger atrial fibrillation and bleeding problems. Imatinib, the original gene-targeted cancer drug, has a relatively favorable cardiac profile but isn't completely benign.

The practical implication is that if you're on a targeted oral cancer drug, your oncology team should be checking blood pressure and asking about palpitations and shortness of breath at every visit. Some of these drugs need an echocardiogram at baseline. Others don't. Your team will tailor the surveillance to the specific drug.

Radiation to the Chest

Radiation is in some ways the longest-tail problem in cardio-oncology. Patients treated with chest radiation for Hodgkin lymphoma, breast cancer, lung cancer, or esophageal cancer may not see heart effects for ten, twenty, or thirty years. The damage shows up as accelerated atherosclerosis (cholesterol-related blockages in the coronary arteries), valve disease (especially aortic valve thickening and leakage), pericardial scarring (the sac around the heart can stiffen), and rhythm problems from scarring of the heart's electrical wiring.

Modern radiation techniques deliver much smaller doses to the heart than the techniques used in the 1970s and 1980s. Patients treated for Hodgkin disease in that older era are the ones who often present in their 50s and 60s with severe coronary artery disease, valve problems, and heart failure all at once. If you're a survivor of childhood or young-adult Hodgkin lymphoma treated decades ago, you almost surely need cardiology surveillance, whether or not you feel well.

What We Watch for During Treatment

The standard cardio-oncology workup before cardiotoxic chemo starts has three pieces. First, a baseline echocardiogram, an ultrasound of the heart, to measure how strongly the heart is pumping (the ejection fraction, or EF) and to look at structure. Second, baseline blood tests for two heart markers: troponin (a protein released when heart muscle is injured) and BNP or NT-proBNP (a hormone released when the heart is under stretch). Third, a careful review of risk factors: blood pressure, diabetes, age, prior heart disease, prior cancer treatment, smoking, family history.

During treatment, we repeat the echocardiogram and the blood markers on a schedule that depends on which drugs you're getting. For trastuzumab in breast cancer, that's typically every three months. For high-dose anthracyclines, we time echocardiograms around dose milestones. For checkpoint inhibitors, the rhythm is set more by symptoms than by routine surveillance, since myocarditis often announces itself rather than sneaking up.

One technique I want to flag because it changes the math is global longitudinal strain, an extra echo measurement that catches subtle weakening of the heart muscle before the main pumping number drops. A drop of 12 to 15 percent in this measurement compared to your baseline is enough to start protective medications, often before you've felt anything. Not every echo lab does strain. If you're starting cardiotoxic treatment, ask whether your echocardiogram will include strain. It's worth the extra five minutes.

Cardioprotective Medications

If your numbers start to slip during treatment, or if you're at high risk going in, we have a small toolkit of medications that protect the heart muscle. None of them are cancer drugs. They're the same medications we use for ordinary heart failure, used earlier and at lower doses.

Beta-blockers like carvedilol or bisoprolol slow the heart and reduce stress on the muscle. ACE inhibitors like lisinopril, or ARBs like losartan or candesartan, relax the blood vessels and reduce the workload on the heart. SGLT2 inhibitors like dapagliflozin and empagliflozin were originally diabetes drugs and have turned out to protect the heart in ways we're still learning about. There's growing evidence they help in cardio-oncology too.

A 2016 randomized trial in breast cancer patients receiving anthracyclines plus or minus trastuzumab showed that an ARB (candesartan) reduced the drop in pumping function during treatment. A follow-up trial a few years later confirmed the same benefit using strain imaging to guide who got treated. Different studies have shown signals for beta-blockers, with results that varied by population and dose. The picture isn't perfectly tidy. The direction is clear: when we treat early, the heart does better.

Dexrazoxane is a different animal. It's an older drug given alongside anthracyclines that reduces the heart muscle injury. It's used selectively, mostly in pediatric oncology and in adults receiving very high cumulative anthracycline doses. There used to be concern about a potential signal for second cancers, which limited its use. Most of that concern has been walked back, and dexrazoxane is having a quiet renaissance in carefully selected patients.

What to Do If Heart Numbers Drop During Chemo

This is the conversation patients dread, and I want to demystify it. If your ejection fraction drops or your strain measurement drifts down or your troponin rises during treatment, that doesn't automatically mean chemo stops. It means a few things happen at once.

We start cardioprotective medications, usually a beta-blocker plus an ACE inhibitor or ARB, sometimes adding an SGLT2 inhibitor. We bring you back for a repeat echo in a defined window, often four to six weeks. We talk to your oncology team about whether the cancer treatment can continue, pause, or shift to a regimen with less heart toxicity. The decision depends on how big the drop is, what cancer you have, what stage it is, what alternative chemo regimens exist, and how you feel.

For trastuzumab in breast cancer, the typical pattern is to pause when the EF drops below 50 percent or by more than 10 points from baseline, start heart medications, and resume the trastuzumab once the function recovers. Many patients can complete the full course this way. For anthracyclines, the calculus depends on how much drug you've already received and how much is left in the planned course. For checkpoint inhibitor myocarditis, we usually stop the drug, often permanently, and treat the inflammation aggressively with steroids.

The point I want to land: a dip in heart function during chemo isn't a death sentence for the chemo plan or for the heart. It's a signal that we need to act. Most patients whose heart function drops during cancer treatment recover with appropriate medication and dose adjustments.

Heart Risk After Radiation

Chest radiation is a different surveillance problem because the timeline is so long. The American Society of Clinical Oncology and the European Society of Cardiology both recommend a baseline cardiac assessment around five years after chest radiation, with periodic echocardiograms after that, and a stress test for anyone with symptoms or a substantial radiation dose to the heart. For Hodgkin lymphoma survivors and breast cancer patients treated with older techniques, surveillance often starts earlier and runs longer.

What we're looking for: blockages in the coronary arteries (which can cause chest pain or heart attack), valve problems (especially aortic stenosis or mitral regurgitation), stiffening of the sac around the heart, and rhythm problems. A coronary CT scan often replaces a stress test as the first-line look at the arteries in radiation survivors, since radiation tends to produce blockages in patterns that stress tests can miss.

If you had chest radiation for cancer at any age, please bring that history to every cardiology visit for the rest of your life. The records get lost. The diagnosis doesn't make it onto the problem list. The patient who can tell me, "I had mantle radiation for Hodgkin's in 1991," is the patient I can take care of properly.

Long-Term Follow-Up for Cancer Survivors

Cancer survivorship has its own surveillance schedule, and the heart piece often gets dropped between oncology and primary care. Here's how I think about it.

Patients who received anthracyclines, trastuzumab, or chest radiation should have a baseline echocardiogram around the time they finish treatment, another at one year, and periodic surveillance after that. The exact interval depends on the cumulative dose, your age, and your other risk factors. For most patients with normal function and no symptoms, every two to five years is reasonable. For higher-risk patients, every year is reasonable. Symptoms (new shortness of breath, chest pain, palpitations, ankle swelling, unexplained fatigue) override the schedule. Get checked sooner.

Beyond imaging, the basics matter more in survivors than in the general population. Tight blood pressure control, statin therapy when indicated, diabetes prevention, smoking cessation, regular aerobic exercise, and a heart-healthy diet are all amplified in their effect when the heart already has a smaller margin. A survivor who takes care of their cardiovascular risk factors after cancer treatment can have outcomes much better than the population average. A survivor who doesn't can lose ground fast.

Common Misconceptions

"Chemo always wrecks the heart." No. Most patients tolerate cardiotoxic chemo without lasting heart problems. The ones who do have problems are usually identified early, treated, and recover. The narrative of the cancer survivor whose heart was destroyed by their treatment comes mostly from older eras of higher doses, fewer protective drugs, and less surveillance.

"If my echo is normal, I'm safe." A normal echocardiogram during or right after chemo is reassuring, and it's not the final word. Anthracycline injury can show up years later. Strain imaging can catch subtle weakening that the basic ejection fraction misses. Long-term surveillance matters after a clean post-treatment scan.

"My oncologist would have told me if I needed a cardiologist." Your oncology team is good. They're also stretched thin, focused on cancer outcomes, and not always set up to track your heart for the next twenty years. Asking for a cardio-oncology referral is a reasonable request before high-risk treatment, and asking for a survivorship cardiology consult two to five years after treatment is reasonable too.

"I had chemo decades ago and I feel fine, so I'm out of the woods." Anthracycline-related heart problems can show up at twenty or thirty years post-treatment. Childhood cancer survivors are the clearest example. If you got cardiotoxic treatment and you've never had a follow-up echo, the right time to get one is now.

"Heart medications will interfere with my chemo." The cardioprotective medications we use, beta-blockers, ACE inhibitors, ARBs, SGLT2 inhibitors, don't interfere with chemotherapy efficacy. They may actually help you stay on the cancer treatment longer by keeping the heart in good enough shape that the oncologist doesn't have to pause.

"Stopping chemo to protect the heart means giving up." Sometimes pausing or modifying chemo is the right answer, and sometimes it isn't. The decision is collaborative between you, your oncologist, and your cardiologist. There are situations where pushing through with heart support is correct, and situations where switching to an alternative regimen is correct. The point is that the conversation should happen openly, with all three voices in the room.

What to Ask Your Oncology and Cardiology Teams

Before starting cardiotoxic cancer treatment, ask your oncologist these questions:

After treatment ends, or if you're a long-term survivor reading this for the first time, ask your primary care doctor or oncologist:

The Cardio-Oncology Clinic Concept

Most academic medical centers and many large community hospitals now have a dedicated cardio-oncology clinic. Whether you need to be seen in one depends on your risk profile. A 35-year-old with early-stage breast cancer getting four cycles of low-dose AC followed by paclitaxel and a clean cardiac history probably doesn't need a separate cardio-oncology visit. A 65-year-old with high blood pressure, diabetes, and a borderline ejection fraction starting high-cumulative-dose anthracyclines for sarcoma absolutely does.

The cardio-oncology visit isn't a one-time thing. It's an ongoing relationship through treatment and into survivorship. The cardiologist coordinates with the oncologist on dose adjustments, manages cardioprotective medications, watches the imaging trends, and stays involved for years after the cancer is in remission. For patients with borderline numbers or unusual situations, that continuity is the difference between a heart that comes through cancer treatment intact and one that doesn't.

If you're in San Diego or North County and you'd like a cardiology voice on your cancer-treatment team, that's exactly the kind of care I provide. The same goes for survivors who finished treatment years ago and have never had cardiac follow-up. It's not too late to start.

Frequently Asked Questions

Can I refuse anthracyclines if I'm worried about my heart?

Sometimes yes, often no. For some cancers (early-stage breast cancer in particular), there are non-anthracycline regimens with similar cure rates. For others (many lymphomas, leukemias, sarcomas), anthracyclines are central to cure and substituting them costs you cancer outcomes. The right way to have this conversation is together with your oncologist, with your individual cardiac risk on the table. Refusing chemotherapy out of fear of heart problems isn't usually the right answer when modern monitoring catches most issues early.

Does dexrazoxane reduce anthracycline cardiotoxicity?

Yes. Dexrazoxane reduces heart muscle injury when given alongside anthracyclines. It's used most often in pediatric oncology and in adults receiving very high cumulative anthracycline doses. Older concerns about dexrazoxane interfering with cancer outcomes or raising risk of second cancers have largely been walked back by more recent data. Whether it's right for you depends on your specific cancer and treatment plan.

If I had a heart attack years ago, can I still get chemo?

Yes, in most cases. A history of heart disease raises your cardio-oncology risk and changes how we monitor you, and it doesn't usually disqualify you from cancer treatment. The decision depends on your current cardiac function, the planned regimen, and the cancer being treated. A pre-treatment cardio-oncology consult is exactly the right move for patients in this situation.

What does "global longitudinal strain" mean on my echo report?

Strain is an extra measurement during an echocardiogram that picks up subtle weakening of heart muscle before the main pumping number (ejection fraction) drops. A drop of 12 to 15 percent from your baseline strain is a signal to start protective medications, sometimes before you've felt anything. Not every lab reports strain. If you're starting cardiotoxic chemo, ask for an echo lab that does it.

I had Hodgkin's in the 1980s. What kind of follow-up do I need now?

Patients treated for Hodgkin lymphoma in that era received what we now consider very high doses of chest radiation, and they have a measurably increased risk of coronary artery disease, valve problems, and pericardial issues that often surface in the 50s and 60s. You should have a cardiology visit, an echocardiogram, and a coronary CT scan if you haven't had one. Stress testing alone can miss the patterns of disease produced by radiation. Lifelong cardiology surveillance is appropriate.

Is it safe to exercise during chemotherapy?

For most patients, yes, and it helps. Aerobic exercise during cancer treatment is associated with better fatigue, better quality of life, and emerging signals that it may help protect the heart. The intensity should be tailored to how you're feeling and to your cardiac status. Talk to your oncology and cardiology teams about a specific plan. The default of "rest during chemo" has been replaced by "stay active to whatever degree your body allows."

My ejection fraction dropped from 60 to 50 during trastuzumab. What now?

A drop from 60 to 50 percent is in the watch-closely zone. Many oncology teams will continue trastuzumab at this level, often with the addition of a beta-blocker and an ACE inhibitor or ARB, and a repeat echo in four to six weeks. If the EF drops further or below 50, the standard move is to pause the trastuzumab, optimize heart medications, and resume once the function recovers. Most patients recover and complete the full course.

Are SGLT2 inhibitors useful in cardio-oncology?

The evidence is still being built. SGLT2 inhibitors (dapagliflozin, empagliflozin) protect the heart in ordinary heart failure regardless of whether the patient has diabetes. There's a growing body of work suggesting they help in chemotherapy-related heart muscle weakening too. Some cardio-oncology programs are starting them in higher-risk patients before or during cardiotoxic chemo. Talk to your cardiologist about whether this fits your situation.

Will my heart function come back to normal after treatment ends?

Often yes. Trastuzumab-related drops are usually reversible. Anthracycline-related drops are less consistently reversible and depend on how early the drop was caught and treated. Modern care, with early initiation of beta-blockers, ACE inhibitors or ARBs, and surveillance, tends to produce good recovery in most patients. The earlier we treat, the better the recovery.

Closing Thought

Cancer treatment has gotten remarkable in the last twenty years. The reason cardio-oncology exists as a field is that we're now winning enough cancer fights that the heart has become the next problem to solve. The good news is that we have tools. We can predict who's at risk, watch the right numbers, treat early, and bring most patients through cardiotoxic treatment with their heart intact. Survivors who pay attention to their cardiovascular health for the rest of their lives can have outcomes that meet or beat the general population.

If you're starting cancer treatment, ask about your heart. If you've finished cancer treatment and never had cardiac follow-up, ask now. The conversation is short, the testing is straightforward, and the payoff is years of healthy life on the other side of cancer.

Disclaimer

This article is educational and isn't a substitute for personal medical advice. Decisions about cancer treatment, cardiac monitoring, and protective medications should be made together with your oncology and cardiology teams, who know your specific history, imaging, and laboratory data.

References

1. Lyon, Alexander R., Teresa López-Fernández, Liam S. Couch, et al. "2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society." European Heart Journal 43, no. 41 (2022): 4229-4361.

2. Armenian, Saro H., Christina Lacchetti, Ana Barac, et al. "Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology 35, no. 8 (2017): 893-911.

3. Curigliano, Giuseppe, David Lenihan, Maurizio Fradley, et al. "Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations." Annals of Oncology 31, no. 2 (2020): 171-190.

4. Gulati, Geeta, Siri Lagethon Heck, Anne Hansen Ree, et al. "Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer Therapy (PRADA): A 2x2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol." European Heart Journal 37, no. 21 (2016): 1671-1680.

5. Thavendiranathan, Paaladinesh, Christine Houbois, John D. Marwick, et al. "Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy." Journal of the American College of Cardiology 77, no. 4 (2021): 392-401.

6. Mahmood, Syed S., Magid Awadalla, Hannah K. Alvi, et al. "Myocarditis in Patients Treated with Immune Checkpoint Inhibitors." Journal of the American College of Cardiology 71, no. 16 (2018): 1755-1764.

7. Cardinale, Daniela, Alessandro Colombo, Giuseppina Lamantia, et al. "Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy." Journal of the American College of Cardiology 55, no. 3 (2010): 213-220.

8. Plana, Juan Carlos, Maurizio Galderisi, Ana Barac, et al. "Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging." Journal of the American Society of Echocardiography 27, no. 9 (2014): 911-939.

9. Lipshultz, Steven E., Vivian I. Franco, Tracie L. Miller, Steven D. Colan, and Stephen E. Sallan. "Cardiovascular Disease in Adult Survivors of Childhood Cancer." Annual Review of Medicine 66 (2015): 161-176.

10. Darby, Sarah C., Marianne Ewertz, Paul McGale, et al. "Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer." New England Journal of Medicine 368, no. 11 (2013): 987-998.

11. Avila, Monica S., Silvia M. Ayub-Ferreira, Marcely R. de Barros Wanderley Jr., et al. "Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial." Journal of the American College of Cardiology 71, no. 20 (2018): 2281-2290.

12. van Nimwegen, Frederika A., Michael Schaapveld, Cecile P. M. Janus, et al. "Cardiovascular Disease after Hodgkin Lymphoma Treatment: 40-Year Disease Risk." JAMA Internal Medicine 175, no. 6 (2015): 1007-1017.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.